Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies

Semin Hematol. 2002 Jul;39(3 Suppl 2):36-8. doi: 10.1053/shem.2002.35986.

Abstract

Progress in molecular biology over the past several years has advanced our understanding of the pathology of leukemia. Researchers have identified a long list of the cytogenetic and molecular abnormalities associated with these diseases. However, a significant unmet need remains for medical therapies for leukemia, especially in older patients.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Alkyl and Aryl Transferases / antagonists & inhibitors*
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Enzyme Inhibitors / administration & dosage
  • Enzyme Inhibitors / therapeutic use
  • Farnesyltranstransferase
  • Hematologic Neoplasms / drug therapy*
  • Hematologic Neoplasms / genetics
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Myelodysplastic Syndromes / drug therapy
  • Myelodysplastic Syndromes / genetics
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Alkyl and Aryl Transferases
  • Farnesyltranstransferase